Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

Institut national de la recherche scientifique

$40,000.00

Smart polymer for antibody purification

EF 2017-18

Résumé
Therapeutic strategies involving human monoclonal antibodies are becoming increasingly prevalent. Thus, the desire to reduce the cost of these drugs is exerting considerable pressure to make the manufacturing process more efficient and cost effective. However, while cell-culturing technology to produce antibodies has improved to deliver yields greater than 5 g/L, purification of the antibody from the medium has become a major process bottleneck. Currently, the use of chromatography columns that selectively capture antibodies from cell culture medium is the most effective method for purifying antibodies. Unfortunately, existing columns are extremely expensive, require harsh cleaning/regeneration processes in order to be reused, and often bind the target in a less-than-stoichiometric amount due to its immobilization on a solid support. To address these shortcomings, BioAstra Technologies Inc. and INRS will develop a recyclable scavenger that can capture and retrieve monoclonal antibodies from cell culture medium, thereby bypassing the need for chromatography. This project represents an excellent opportunity to train HQP in this area, which is of great social and economic importance. The output of this project will constitute a major technological advance that will reduce the cost of monoclonal antibodies and their corresponding therapies.
Programme
Collaborative Research and Development Grants
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
493244-2015
Name nom
Gauthier, Marc
Department département
Centre Énergie, Matériaux et Télécommunications (ÉMT) Varennes
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2015
Award amount
40000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
2
Nb partie
2
Application title
Smart polymer for antibody purification
Keyword
NSERC
Application summary
Therapeutic strategies involving human monoclonal antibodies are becoming increasingly prevalent. Thus, the desire to reduce the cost of these drugs is exerting considerable pressure to make the manufacturing process more efficient and cost effective. However, while cell-culturing technology to produce antibodies has improved to deliver yields greater than 5 g/L, purification of the antibody from the medium has become a major process bottleneck. Currently, the use of chromatography columns that selectively capture antibodies from cell culture medium is the most effective method for purifying antibodies. Unfortunately, existing columns are extremely expensive, require harsh cleaning/regeneration processes in order to be reused, and often bind the target in a less-than-stoichiometric amount due to its immobilization on a solid support. To address these shortcomings, BioAstra Technologies Inc. and INRS will develop a recyclable scavenger that can capture and retrieve monoclonal antibodies from cell culture medium, thereby bypassing the need for chromatography. This project represents an excellent opportunity to train HQP in this area, which is of great social and economic importance. The output of this project will constitute a major technological advance that will reduce the cost of monoclonal antibodies and their corresponding therapies.